Scinai Immunotherapeutics Ltd.
SCNI
$2.44
-$0.0734-2.92%
NASDAQ
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 4.51M | 5.11M | 5.11M | 5.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -9.00K | 3.19M | 3.19M | 3.19M |
| Total Operating Expenses | -- | 9.71M | 14.62M | 14.68M | 15.35M |
| Operating Income | -- | -9.71M | -14.62M | -14.68M | -15.35M |
| Income Before Tax | -- | -12.71M | -10.91M | -3.03M | -2.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -12.71 | -10.91 | -3.03 | -2.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -12.71M | -10.91M | -3.03M | -2.25M |
| EBIT | -- | -9.71M | -14.62M | -14.68M | -15.35M |
| EBITDA | -- | -9.19M | -14.05M | -14.11M | -14.78M |
| EPS Basic | -- | -145.46K | -125.32K | -999.20 | -20.38K |
| Normalized Basic EPS | -- | -18.59 | -15.44 | -15.44 | -18.47 |
| EPS Diluted | -- | -157.42K | -165.80K | -41.49K | -60.96K |
| Normalized Diluted EPS | -- | -18.59 | -15.44 | -15.44 | -18.47 |
| Average Basic Shares Outstanding | -- | 1.43M | 1.33M | 1.05M | 900.30K |
| Average Diluted Shares Outstanding | -- | 100.00 | 100.00 | 0.00 | 0.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |